Advertisement

Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis

Published:November 17, 2022DOI:https://doi.org/10.1016/j.jns.2022.120501

      Highlights

      • Cerebral gray matter volume is a sensitive and clinically relevant measurement of assessing the neuroprotective effect of disease-modifying therapies in multiple sclerosis.
      • Gray matter atrophy is more predictive of conversion from clinically isolated syndrome to multiple sclerosis than white matter disease.
      • Gray matter atrophy has been more strongly associated with cognitive impairment and disability progression than white matter disease.
      • In this pilot study, glatiramer acetate was associated with preservation of cerebral gray matter and whole brain volumes.

      Abstract

      Background and purpose

      Cerebral gray matter (GM) atrophy is a proposed measure of neuroprotection in multiple sclerosis (MS). Glatiramer acetate (GA) limits clinical relapses, MRI lesions, and whole brain atrophy in relapsing-remitting MS (RRMS). The effect of GA on GM atrophy remains unclear. We assessed GM atrophy in patients with RRMS starting GA therapy in comparison to a cohort of patients with clinically benign RRMS (BMS).

      Design/methods

      We studied 14 patients at GA start [age (mean ± SD) 44.2 ± 7.0 years, disease duration (DD) 7.2 ± 6.4 years, Expanded Disability Status Scale score (EDSS) (median,IQR) 1.0,2.0] and 6 patients with BMS [age 43.0 ± 6.1 years, DD 18.1 ± 8.4 years, EDSS 0.5,1.0]. Brain MRI was obtained at baseline and one year later (both groups) and two years later in all patients in the GA group except one who was lost to follow-up. Semi-automated algorithms assessed cerebral T2 hyperintense lesion volume (T2LV), white matter fraction (WMF), GM fraction (GMF), and brain parenchymal fraction (BPF). The exact Wilcoxon-Mann-Whitney test compared the groups. The Wilcoxon signed rank test assessed longitudinal changes within groups.

      Results

      During the first year, MRI changes did not differ significantly between groups (p > 0.15). Within the BMS group, WMF and BPF decreased during the first year (p = 0.03). Within the GA group, there was no significant change in MRI measures during each annual period (p > 0.05). Over two years, the GA group had a significant increase in T2LV and decrease in WMF (p < 0.05), while GMF and BPF remained stable (p > 0.05). MRI changes in brain volumes (GMF or WMF) in the first year in the GA group were not significantly different from those in the BMS group (p > 0.5).

      Conclusions

      In this pilot study with a small sample size, patients with RRMS started on GA did not show significant GM or whole brain atrophy over 2 years, resembling MS patients with a clinically benign disease course.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vollmer T.
        • Signorovitch J.
        • Huynh L.
        • et al.
        The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.
        J. Neurol. Sci. Oct 2015; 357: 8-18https://doi.org/10.1016/j.jns.2015.07.014
        • Battaglini M.
        • Gentile G.
        • Luchetti L.
        • et al.
        Lifespan normative data on rates of brain volume changes.
        Neurobiol. Aging. 2019; 09: 30-37https://doi.org/10.1016/j.neurobiolaging.2019.05.010
        • Andravizou A.
        • Dardiotis E.
        • Artemiadis A.
        • et al.
        Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options.
        Auto Immun Highlights. Dec 2019; 10: 7https://doi.org/10.1186/s13317-019-0117-5
        • Healy B.
        • Valsasina P.
        • Filippi M.
        • Bakshi R.
        Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis.
        J. Neurol. Neurosurg. Psychiatry. Nov 2009; 80: 1218-1223https://doi.org/10.1136/jnnp.2008.154732
        • Bermel R.A.
        • Bakshi R.
        The measurement and clinical relevance of brain atrophy in multiple sclerosis.
        Lancet Neurol. Feb 2006; 5: 158-170https://doi.org/10.1016/S1474-4422(06)70349-0
        • Sanfilipo M.P.
        • Benedict R.H.
        • Sharma J.
        • Weinstock-Guttman B.
        • Bakshi R.
        The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.
        Neuroimage. Jul 15 2005; 26: 1068-1077https://doi.org/10.1016/j.neuroimage.2005.03.008
        • Dalton C.M.
        • Chard D.T.
        • Davies G.R.
        • et al.
        Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.
        Brain. May 2004; 127: 1101-1107https://doi.org/10.1093/brain/awh126
        • Pagani E.
        • Rocca M.A.
        • Gallo A.
        • et al.
        Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype.
        AJNR Am. J. Neuroradiol. Feb 2005; 26: 341-346
        • Damjanovic D.
        • Valsasina P.
        • Rocca M.A.
        • et al.
        Hippocampal and deep gray matter nuclei atrophy is relevant for explaining cognitive impairment in MS: a multicenter study.
        AJNR Am. J. Neuroradiol. Jan 2017; 38: 18-24https://doi.org/10.3174/ajnr.A4952
        • Bornstein M.B.
        • Miller A.
        • Slagle S.
        • et al.
        A pilot trial of cop 1 in exacerbating-remitting multiple sclerosis.
        N. Engl. J. Med. Aug 13 1987; 317: 408-414https://doi.org/10.1056/NEJM198708133170703
        • Johnson K.P.
        • Brooks B.R.
        • Cohen J.A.
        • et al.
        Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The copolymer 1 multiple sclerosis study group.
        Neurology. Jul 1995; 45: 1268-1276https://doi.org/10.1212/wnl.45.7.1268
        • Ruggieri M.
        • Avolio C.
        • Livrea P.
        • Trojano M.
        Glatiramer acetate in multiple sclerosis: a review.
        CNS Drug Rev. 2007; 13: 178-191https://doi.org/10.1111/j.1527-3458.2007.00010.x
        • Neuhaus O.
        • Farina C.
        • Yassouridis A.
        • et al.
        Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.
        Proc. Natl. Acad. Sci. U. S. A. Jun 20 2000; 97: 7452-7457https://doi.org/10.1073/pnas.97.13.7452
        • Comi G.
        • Filippi M.
        • Wolinsky J.S.
        European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer acetate study group.
        Ann. Neurol. Mar 2001; 49: 290-297
        • Wolinsky J.S.
        • Narayana P.A.
        • Johnson K.P.
        Center MSSGatMA. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple sclerosis study group and the MRI analysis center.
        Mult. Scler. Feb 2001; 7: 33-41https://doi.org/10.1177/135245850100700107
        • Ford C.C.
        • Johnson K.P.
        • Lisak R.P.
        • et al.
        A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.
        Mult. Scler. Jun 2006; 12: 309-320https://doi.org/10.1191/135248506ms1318oa
        • Rovaris M.
        • Comi G.
        • Rocca M.A.
        • et al.
        Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial.
        Mult. Scler. May 2007; 13: 502-508https://doi.org/10.1177/1352458506070704
        • Johnson K.P.
        • Brooks B.R.
        • Ford C.C.
        • et al.
        Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 multiple sclerosis study group.
        Mult. Scler. Aug 2000; 6: 255-266https://doi.org/10.1177/135245850000600407
        • Sormani M.P.
        • Rovaris M.
        • Valsasina P.
        • Wolinsky J.S.
        • Comi G.
        • Filippi M.
        Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis.
        Neurology. Apr 27 2004; 62: 1432-1434https://doi.org/10.1212/01.wnl.0000120663.85143.b3
        • Khan O.
        • Rieckmann P.
        • Boyko A.
        • et al.
        Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
        Mult. Scler. 2017; 23: 818-829https://doi.org/10.1177/1352458516664033
        • Crescenzo F.
        • Marastoni D.
        • Zuco C.
        • et al.
        Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
        Mult Scler Relat Disord. Jan 2019; 27: 305-311https://doi.org/10.1016/j.msard.2018.11.009
        • Gauthier S.A.
        • Berger A.M.
        • Liptak Z.
        • et al.
        Rate of brain atrophy in benign vs early multiple sclerosis.
        Arch. Neurol. Feb 2009; 66: 234-237https://doi.org/10.1001/archneurol.2008.567
        • Polman C.H.
        • Reingold S.C.
        • Edan G.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria".
        Ann. Neurol. Dec 2005; 58: 840-846https://doi.org/10.1002/ana.20703
        • Wei X.
        • Warfield S.K.
        • Zou K.H.
        • et al.
        Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy.
        J. Magn. Reson. Imaging. Feb 2002; 15: 203-209https://doi.org/10.1002/jmri.10053
        • Khalid F.
        • Tauhid S.
        • Chua A.S.
        • et al.
        A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
        Int J Neurosci. May 2017; 127: 396-403https://doi.org/10.1080/00207454.2016.1185421
        • Sharma J.
        • Sanfilipo M.P.
        • Benedict R.H.
        • Weinstock-Guttman B.
        • Munschauer F.E.
        • Bakshi R.
        Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.
        AJNR Am. J. Neuroradiol. Jun-Jul 2004; 25: 985-996
        • Henry R.G.
        • Shieh M.
        • Amirbekian B.
        • Chung S.
        • Okuda D.T.
        • Pelletier D.
        Connecting white matter injury and thalamic atrophy in clinically isolated syndromes.
        J. Neurol. Sci. Jul 15 2009; 282: 61-66https://doi.org/10.1016/j.jns.2009.02.379
        • Peterson J.W.
        • Bö L.
        • Mörk S.
        • Chang A.
        • Trapp B.D.
        Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.
        Ann. Neurol. Sep 2001; 50: 389-400https://doi.org/10.1002/ana.1123
        • Pirko I.
        • Lucchinetti C.F.
        • Sriram S.
        • Bakshi R.
        Gray matter involvement in multiple sclerosis.
        Neurology. Feb 27 2007; 68: 634-642https://doi.org/10.1212/01.wnl.0000250267.85698.7a
        • Calabrese M.
        • Filippi M.
        • Gallo P.
        Cortical lesions in multiple sclerosis.
        Nat. Rev. Neurol. Aug 2010; 6: 438-444https://doi.org/10.1038/nrneurol.2010.93
        • Singhal T.
        • O'Connor K.
        • Dubey S.
        • et al.
        Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study.
        Neurol Neuroimmunol Neuroinflamm. 2019; 6 (e587)https://doi.org/10.1212/NXI.0000000000000587
        • Zurawski J.
        • Tauhid S.
        • Chu R.
        • et al.
        7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
        Mult. Scler. 2020; 26: 177-187https://doi.org/10.1177/1352458519885106
        • Ratchford J.N.
        • Endres C.J.
        • Hammoud D.A.
        • et al.
        Decreased microglial activation in MS patients treated with glatiramer acetate.
        J. Neurol. Jun 2012; 259: 1199-1205https://doi.org/10.1007/s00415-011-6337-x
        • Filippi M.
        • Rovaris M.
        • Rocca M.A.
        • et al.
        Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
        Neurology. Aug 28 2001; 57: 731-733https://doi.org/10.1212/wnl.57.4.731